Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016169 | 0.81 | CYP2C9 (0.49) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21978883 | 0.78 | ATM (0.43) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL30901264 | 0.78 | ATM (0.43) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22017133 | 0.76 | HSP90AA1 (0.44) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22016488 | 0.76 | ATM (0.41) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL31223914 | 0.75 | ATM (0.43) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8366327 | 0.74 | PTGDR2 (0.54) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL22417980 | 0.72 | KDM4E (0.50) | ATMKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8140534 | 0.70 | ATM (0.53) | ATMKDM4EALDH1A1MEN1HCRTR1 | |
| SCHEMBL890554 | 0.70 | PIK3CD (0.43) | ATMKDM4EALDH1A1SMN1; SMN2HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | ATM 3786/4885KDM4E 1442/4885ALDH1A1 823/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ATM 4085/4885KDM4E 1209/4885ALDH1A1 791/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | ATM 2532/4885KDM4E 2655/4885ALDH1A1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.